Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences

@inproceedings{Yan2018PrognosticFF,
  title={Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences},
  author={Xinyu Yan and Shouyue Zhang and Yun Deng and Peiqi Wang and Qianqian Hou and Heng Xu},
  booktitle={Front. Pharmacol.},
  year={2018}
}
Checkpoint inhibitor (CPI) based immunotherapy (i.e., anit-CTLA-4/PD-1/PD-L1 antibodies) can effectively prolong overall survival of patients across several cancer types at the advanced stage. However, only part of patients experience objective responses from such treatments, illustrating large individual differences in terms of both efficacy and adverse drug reactions. Through the observation on a series of CPI based clinical trials in independent patient cohorts, associations of multiple… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
0 Citations
155 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 155 references

Similar Papers

Loading similar papers…